Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jul 1;3(4):598-612.
doi: 10.1021/acsptsci.0c00048. eCollection 2020 Aug 14.

Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies

Monika Spaczyńska  1 , Susana F Rocha  1 , Eduardo Oliver  1   2
Affiliations
Review

Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies

Monika Spaczyńska et al. ACS Pharmacol Transl Sci. .

Abstract

Pulmonary arterial hypertension is a rare and devastating disease characterized by an abnormal chronic increase in pulmonary arterial pressure above 20 mmHg at rest, with a poor prognosis if not treated. Currently, there is not a single fully effective therapy, even though a dozen of drugs have been developed in the last decades. Pulmonary arterial hypertension is a multifactorial disease, meaning that several molecular mechanisms are implicated in its pathology. The main molecular pathways regulating the pulmonary vasomotor tone-endothelin, nitric oxide, and prostacyclin-are the most biologically and therapeutically explored to date. However, drugs targeting these pathways have already found their limitations. In the last years, translational research and clinical trials have made a strong effort in suggesting and testing novel therapeutic strategies for this disease. These approaches involve targeting the main molecular pathways with novel drugs, drug repurposing for novel targets, and also using combinatorial therapies. In this review, we summarize current strategies and drugs targeting the endothelin, nitric oxide, and prostacyclin pathways, as well as, the emerging new drugs proposed to cope with vascular remodelling, metabolic switch, perivascular inflammation, epigenetic modifications, estrogen deregulation, serotonin, and other neurohumoral mechanisms characteristic of this disease. Nowadays, pulmonary arterial hypertension remains an incurable disease; however, the incoming new knowledge makes us believe that new promising therapies are coming to the clinical arena soon.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Hallmarks of PAH. The initial endothelial dysfunction compromising vascular dilation and permeability is followed by perivascular inflammation, fibrosis, metabolic dysfunction, and vascular remodelling, all contributing to the rise in mPAP, RV hypertrophy, failure, and premature death: mPAP, mean pulmonary arterial pressure; RV, right ventricle; PH, pulmonary hypertension; PAH, pulmonary arterial hypertension; CTEPH, chronic thromboembolic PH; PVR, pulmonary vascular resistance; PCWP, pulmonary capillary wedge pressure. Individual illustrations were kindly provided by Dr Carlos Galan-Arriola.
Figure 2
Figure 2
Current targets and therapies in PAH. ET, indicates endothelin; ETA, endothelin receptor type A; ETB, endothelin receptor type B; PGI2, prostaglandin I2; IP, PGI2 receptor; NO, nitric oxide; PDE5, phosphodiesterase type 5; sGC, soluble guanylate cyclase; GMP, guanosine triphosphate; cGMP, cyclic guanosine triphosphate; cAMP, cyclic adenosine monophosphate; ATP, adenosine triphosphate; AC, adenyl cyclase; Ca-Ch, calcium channel. Individual illustrations were kindly provided by Dr. Carlos Galan-Arriola.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Farber H. W.; Miller D. P.; Poms A. D.; Badesch D. B.; Frost A. E.; Muros-Le Rouzic E.; Romero A. J.; Benton W. W.; Elliott C. G.; McGoon M. D.; Benza R. L. (2015) Five-Year outcomes of patients enrolled in the REVEAL Registry. Chest 148 (4), 1043.10.1378/chest.15-0300. - DOI - PubMed
    1. Galie N.; Humbert M.; Vachiery J.-L.; Gibbs S.; Lang I.; Torbicki A.; Simonneau G.; Peacock A.; Vonk Noordegraaf A.; Beghetti M.; Ghofrani A.; Gomez Sanchez M. A.; Hansmann G.; Klepetko W.; Lancellotti P.; Matucci M.; McDonagh T.; Pierard L. A.; Trindade P. T.; Zompatori M.; Hoeper M. (2016) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur. Heart J. 37 (1), 67.10.1093/eurheartj/ehv317. - DOI - PubMed
    1. Prins K. W.; Thenappan T. (2016) World Health Organization Group I Pulmonary Hypertension: Epidemiology and Pathophysiology.. Cardiol Clin 34 (3), 363–74. 10.1016/j.ccl.2016.04.001. - DOI - PMC - PubMed
    1. Wijeratne D. T.; Lajkosz K.; Brogly S. B.; Lougheed M. D.; Jiang L.; Housin A.; Barber D.; Johnson A.; Doliszny K. M.; Archer S. L. (2018) Increasing Incidence and Prevalence of World Health Organization Groups 1 to 4 Pulmonary Hypertension: A Population-Based Cohort Study in Ontario, Canada.. Circ Cardiovasc Qual Outcomes 11 (2), e00397310.1161/CIRCOUTCOMES.117.003973. - DOI - PMC - PubMed
    1. Simonneau G.; Montani D.; Celermajer D. S.; Denton C. P.; Gatzoulis M. A.; Krowka M.; Williams P. G.; Souza R. (2019) Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur. Respir. J. 53 (1), 1801913.10.1183/13993003.01913-2018. - DOI - PMC - PubMed

LinkOut - more resources